- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.36 Å
- Oligo State
- homo-octamer
- Ligands
- 12 x C2R: 5-AMINO-1-(5-O-PHOSPHONO-BETA-D-RIBOFURANOSYL)-1H-IMIDAZOLE-4-CARBOXYLIC ACID(Non-covalent)
- 4 x OK8: (2~{S})-2-[[5-azanyl-1-[(2~{R},3~{R},4~{S},5~{R})-3,4-bis(oxidanyl)-5-(phosphonooxymethyl)oxolan-2-yl]imidazol-4-yl]car bonylamino]butanedioic acid(Non-covalent)
OK8.2: 20 residues within 4Å:- Chain A: K.17, A.41, G.42, N.43, E.97, V.99, R.101, G.106, S.107, D.137, D.189, M.190, K.191, D.212, S.213, W.214, R.215, K.228, R.232
- Ligands: IMD.3
20 PLIP interactions:20 interactions with chain A- Hydrogen bonds: A:G.42, A:N.43, A:S.107, A:D.189, A:W.214, A:R.232, A:R.232
- Water bridges: A:K.17, A:S.107, A:S.107, A:D.212, A:R.215, A:R.215, A:K.228
- Salt bridges: A:K.17, A:R.101, A:R.215, A:K.228, A:R.232
- pi-Cation interactions: A:R.232
OK8.18: 20 residues within 4Å:- Chain C: K.17, A.41, G.42, N.43, E.97, V.99, R.101, G.106, S.107, D.137, D.189, M.190, K.191, D.212, S.213, W.214, R.215, K.228, R.232
- Ligands: IMD.19
20 PLIP interactions:20 interactions with chain C- Hydrogen bonds: C:G.42, C:N.43, C:S.107, C:D.189, C:W.214, C:R.232, C:R.232
- Water bridges: C:K.17, C:S.107, C:S.107, C:D.212, C:R.215, C:R.215, C:K.228
- Salt bridges: C:K.17, C:R.101, C:R.215, C:K.228, C:R.232
- pi-Cation interactions: C:R.232
OK8.34: 20 residues within 4Å:- Chain E: K.17, A.41, G.42, N.43, E.97, V.99, R.101, G.106, S.107, D.137, D.189, M.190, K.191, D.212, S.213, W.214, R.215, K.228, R.232
- Ligands: IMD.35
20 PLIP interactions:20 interactions with chain E- Hydrogen bonds: E:G.42, E:N.43, E:S.107, E:D.189, E:W.214, E:R.232, E:R.232
- Water bridges: E:K.17, E:S.107, E:S.107, E:D.212, E:R.215, E:R.215, E:K.228
- Salt bridges: E:K.17, E:R.101, E:R.215, E:K.228, E:R.232
- pi-Cation interactions: E:R.232
OK8.50: 20 residues within 4Å:- Chain G: K.17, A.41, G.42, N.43, E.97, V.99, R.101, G.106, S.107, D.137, D.189, M.190, K.191, D.212, S.213, W.214, R.215, K.228, R.232
- Ligands: IMD.51
20 PLIP interactions:20 interactions with chain G- Hydrogen bonds: G:G.42, G:N.43, G:S.107, G:D.189, G:W.214, G:R.232, G:R.232
- Water bridges: G:K.17, G:S.107, G:S.107, G:D.212, G:R.215, G:R.215, G:K.228
- Salt bridges: G:K.17, G:R.101, G:R.215, G:K.228, G:R.232
- pi-Cation interactions: G:R.232
- 8 x IMD: IMIDAZOLE(Non-covalent)
IMD.3: 4 residues within 4Å:- Chain A: E.97, V.99, F.129
- Ligands: OK8.2
1 PLIP interactions:1 interactions with chain A- Water bridges: A:S.107
IMD.11: 5 residues within 4Å:- Chain B: E.97, V.99, F.129, D.137
- Ligands: C2R.10
2 PLIP interactions:2 interactions with chain B- Hydrogen bonds: B:S.107, B:S.107
IMD.19: 4 residues within 4Å:- Chain C: E.97, V.99, F.129
- Ligands: OK8.18
1 PLIP interactions:1 interactions with chain C- Water bridges: C:S.107
IMD.27: 5 residues within 4Å:- Chain D: E.97, V.99, F.129, D.137
- Ligands: C2R.26
2 PLIP interactions:2 interactions with chain D- Hydrogen bonds: D:S.107, D:S.107
IMD.35: 4 residues within 4Å:- Chain E: E.97, V.99, F.129
- Ligands: OK8.34
2 PLIP interactions:2 interactions with chain E- Hydrogen bonds: E:E.97
- Water bridges: E:S.107
IMD.43: 5 residues within 4Å:- Chain F: E.97, V.99, F.129, D.137
- Ligands: C2R.42
3 PLIP interactions:3 interactions with chain F- Hydrogen bonds: F:E.97, F:S.107, F:S.107
IMD.51: 4 residues within 4Å:- Chain G: E.97, V.99, F.129
- Ligands: OK8.50
2 PLIP interactions:2 interactions with chain G- Hydrogen bonds: G:E.97
- Water bridges: G:S.107
IMD.59: 5 residues within 4Å:- Chain H: E.97, V.99, F.129, D.137
- Ligands: C2R.58
3 PLIP interactions:3 interactions with chain H- Hydrogen bonds: H:E.97, H:S.107, H:S.107
- 40 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
EDO.4: 8 residues within 4Å:- Chain A: I.73, K.74, A.168, F.194, I.203, V.204, L.205, I.411
Ligand excluded by PLIPEDO.5: 3 residues within 4Å:- Chain A: E.315, D.319
- Chain B: Y.122
Ligand excluded by PLIPEDO.6: 7 residues within 4Å:- Chain A: V.31, L.33, P.89, Q.90, C.91, A.206, D.207
Ligand excluded by PLIPEDO.7: 8 residues within 4Å:- Chain A: E.317, G.318, D.319, G.320, Y.345
- Chain B: E.177, K.178, L.181
Ligand excluded by PLIPEDO.8: 8 residues within 4Å:- Chain A: R.102, E.177, K.178, L.181
- Chain B: E.317, G.318, D.319, G.320
Ligand excluded by PLIPEDO.12: 8 residues within 4Å:- Chain B: I.73, K.74, A.168, F.194, I.203, V.204, L.205, I.411
Ligand excluded by PLIPEDO.13: 4 residues within 4Å:- Chain A: Y.122
- Chain B: E.315, Y.316, D.319
Ligand excluded by PLIPEDO.14: 9 residues within 4Å:- Chain B: V.31, L.33, A.76, P.89, Q.90, C.91, M.93, A.206, D.207
Ligand excluded by PLIPEDO.15: 5 residues within 4Å:- Chain B: S.262, G.292, P.294, N.395, V.398
Ligand excluded by PLIPEDO.16: 3 residues within 4Å:- Chain B: G.118, Y.119, K.120
Ligand excluded by PLIPEDO.20: 8 residues within 4Å:- Chain C: I.73, K.74, A.168, F.194, I.203, V.204, L.205, I.411
Ligand excluded by PLIPEDO.21: 3 residues within 4Å:- Chain C: E.315, D.319
- Chain D: Y.122
Ligand excluded by PLIPEDO.22: 7 residues within 4Å:- Chain C: V.31, L.33, P.89, Q.90, C.91, A.206, D.207
Ligand excluded by PLIPEDO.23: 8 residues within 4Å:- Chain C: E.317, G.318, D.319, G.320, Y.345
- Chain D: E.177, K.178, L.181
Ligand excluded by PLIPEDO.24: 8 residues within 4Å:- Chain C: R.102, E.177, K.178, L.181
- Chain D: E.317, G.318, D.319, G.320
Ligand excluded by PLIPEDO.28: 8 residues within 4Å:- Chain D: I.73, K.74, A.168, F.194, I.203, V.204, L.205, I.411
Ligand excluded by PLIPEDO.29: 4 residues within 4Å:- Chain C: Y.122
- Chain D: E.315, Y.316, D.319
Ligand excluded by PLIPEDO.30: 9 residues within 4Å:- Chain D: V.31, L.33, A.76, P.89, Q.90, C.91, M.93, A.206, D.207
Ligand excluded by PLIPEDO.31: 5 residues within 4Å:- Chain D: S.262, G.292, P.294, N.395, V.398
Ligand excluded by PLIPEDO.32: 3 residues within 4Å:- Chain D: G.118, Y.119, K.120
Ligand excluded by PLIPEDO.36: 8 residues within 4Å:- Chain E: I.73, K.74, A.168, F.194, I.203, V.204, L.205, I.411
Ligand excluded by PLIPEDO.37: 3 residues within 4Å:- Chain E: E.315, D.319
- Chain F: Y.122
Ligand excluded by PLIPEDO.38: 7 residues within 4Å:- Chain E: V.31, L.33, P.89, Q.90, C.91, A.206, D.207
Ligand excluded by PLIPEDO.39: 8 residues within 4Å:- Chain E: E.317, G.318, D.319, G.320, Y.345
- Chain F: E.177, K.178, L.181
Ligand excluded by PLIPEDO.40: 8 residues within 4Å:- Chain E: R.102, E.177, K.178, L.181
- Chain F: E.317, G.318, D.319, G.320
Ligand excluded by PLIPEDO.44: 8 residues within 4Å:- Chain F: I.73, K.74, A.168, F.194, I.203, V.204, L.205, I.411
Ligand excluded by PLIPEDO.45: 4 residues within 4Å:- Chain E: Y.122
- Chain F: E.315, Y.316, D.319
Ligand excluded by PLIPEDO.46: 9 residues within 4Å:- Chain F: V.31, L.33, A.76, P.89, Q.90, C.91, M.93, A.206, D.207
Ligand excluded by PLIPEDO.47: 5 residues within 4Å:- Chain F: S.262, G.292, P.294, N.395, V.398
Ligand excluded by PLIPEDO.48: 3 residues within 4Å:- Chain F: G.118, Y.119, K.120
Ligand excluded by PLIPEDO.52: 8 residues within 4Å:- Chain G: I.73, K.74, A.168, F.194, I.203, V.204, L.205, I.411
Ligand excluded by PLIPEDO.53: 3 residues within 4Å:- Chain G: E.315, D.319
- Chain H: Y.122
Ligand excluded by PLIPEDO.54: 7 residues within 4Å:- Chain G: V.31, L.33, P.89, Q.90, C.91, A.206, D.207
Ligand excluded by PLIPEDO.55: 8 residues within 4Å:- Chain G: E.317, G.318, D.319, G.320, Y.345
- Chain H: E.177, K.178, L.181
Ligand excluded by PLIPEDO.56: 8 residues within 4Å:- Chain G: R.102, E.177, K.178, L.181
- Chain H: E.317, G.318, D.319, G.320
Ligand excluded by PLIPEDO.60: 8 residues within 4Å:- Chain H: I.73, K.74, A.168, F.194, I.203, V.204, L.205, I.411
Ligand excluded by PLIPEDO.61: 4 residues within 4Å:- Chain G: Y.122
- Chain H: E.315, Y.316, D.319
Ligand excluded by PLIPEDO.62: 9 residues within 4Å:- Chain H: V.31, L.33, A.76, P.89, Q.90, C.91, M.93, A.206, D.207
Ligand excluded by PLIPEDO.63: 5 residues within 4Å:- Chain H: S.262, G.292, P.294, N.395, V.398
Ligand excluded by PLIPEDO.64: 3 residues within 4Å:- Chain H: G.118, Y.119, K.120
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Skerlova, J. et al., Crystal structures of human PAICS reveal substrate and product binding of an emerging cancer target. J.Biol.Chem. (2020)
- Release Date
- 2020-07-08
- Peptides
- Multifunctional protein ADE2: ABCDEFGH
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
AD
BE
AF
BG
AH
B
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.36 Å
- Oligo State
- homo-octamer
- Ligands
- 12 x C2R: 5-AMINO-1-(5-O-PHOSPHONO-BETA-D-RIBOFURANOSYL)-1H-IMIDAZOLE-4-CARBOXYLIC ACID(Non-covalent)
- 4 x OK8: (2~{S})-2-[[5-azanyl-1-[(2~{R},3~{R},4~{S},5~{R})-3,4-bis(oxidanyl)-5-(phosphonooxymethyl)oxolan-2-yl]imidazol-4-yl]car bonylamino]butanedioic acid(Non-covalent)
- 8 x IMD: IMIDAZOLE(Non-covalent)
- 40 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Skerlova, J. et al., Crystal structures of human PAICS reveal substrate and product binding of an emerging cancer target. J.Biol.Chem. (2020)
- Release Date
- 2020-07-08
- Peptides
- Multifunctional protein ADE2: ABCDEFGH
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
AD
BE
AF
BG
AH
B